Apnimed, Inc.

Overview

Compare with another stock.

• TickerAPMD on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersCambridge, Massachusetts¹
• Incorporated inDE²
• Business address39 John F. Kennedy Street, 4Th Flr., Cambridge, Ma 02138²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Apnimed, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Apnimed, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerKevin Robert Lind Jul 30, 2026 to now³
• PresidentDennis Patrick Molnar Jul 30, 2026 to now⁴
• Chief financial officerMichael B. Kelly Jul 30, 2026 to now⁵
• Chief operating officerDennis Patrick Molnar Jul 30, 2026 to now⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerBarry G. Wohl named Nov 1, 2022 to Mar 27, 2026¹²
• Executive OfficerRamzi C. Benamar named Dec 8, 2025 to Mar 27, 2026¹²
• Executive OfficerMichael G. Rogers named Nov 1, 2022 to Nov 8, 2023¹³
• DirectorFrancois C. Beaubien named Nov 8, 2023 to Mar 27, 2026¹²
• DirectorIsaac C. Cheng named Nov 1, 2022 to Mar 27, 2026¹²
• DirectorJoseph C. Avellone named Nov 1, 2022 to Mar 27, 2026¹²
• DirectorRuoxi C. Hu named Dec 23, 2022¹⁴
• DirectorStefan C. Larson named Nov 1, 2022 to Dec 23, 2022¹⁴
• DirectorJames C. Galeota named Nov 1, 2022¹⁵
• DirectorRosy C. Hu named Nov 1, 2022¹⁵

Timeline

1. Sep 8, 20268-K Results of operations¹⁶
2. Aug 3, 20268-K Bylaws or fiscal year changed¹⁷
3. Jul 30, 2026New chief executive Kevin Robert Lind becomes CEO³

Calendar

Coming up

1. Dec 8, 2026Reports results for the quarter ending Sep/2026¹⁸

When it reported results

1. Sep 8, 2026Reported quarterly or annual results¹⁶

Drug trials and FDA: recently

1. Mar 10, 2025Phase 3 trial completed Phase 3 trial of AD109 in OSA: primary completion Mar 10, 2025, results posted Sep 11, 2026 (ClinicalTrials.gov NCT05813275).¹⁹
2. Jul 20, 2022Phase 2 trial completed Phase 2 trial of AD109, AD504 and others in OSA - Obstructive Sleep Apnea: primary completion Jul 20, 2022, results posted Aug 12, 2026 (ClinicalTrials.gov NCT05071612).²⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

48 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 21 insider forms, 2 large holders, 9 private raises, 13 other. The latest 20:

1. Sep 8, 2026S-8 EDGAR
2. Sep 8, 202610-Q EDGAR
3. Sep 8, 20268-K EDGAR
4. Aug 7, 2026SCHEDULE 13G EDGAR
5. Aug 6, 2026SCHEDULE 13G EDGAR
6. Aug 5, 20264 EDGAR
7. Aug 5, 20264 EDGAR
8. Aug 3, 20264 EDGAR
9. Aug 3, 20268-K EDGAR
10. Aug 3, 20264 EDGAR
11. Aug 3, 20264 EDGAR
12. Aug 3, 20264 EDGAR
13. Aug 3, 20264 EDGAR
14. Aug 3, 20264 EDGAR
15. Aug 3, 20264 EDGAR
16. Aug 3, 20264 EDGAR
17. Jul 31, 2026S-8 EDGAR
18. Jul 31, 2026424B4 EDGAR
19. Jul 30, 2026EFFECT EDGAR
20. Jul 30, 2026CERT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Ameriprise FinancialSCHEDULE 13G, 1 filing Aug 7, 2026²¹
• Tao Capital Management LPSCHEDULE 13G, 1 filing Aug 6, 2026²²

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Mar 11, 2026Raised $25 million in a private offering of equity¹² Form D: 2 investors so far Form D
2. Sep 17, 2025Raised $35 million in a private offering of debt²³ Form D: 7 investors so far Form D
3. Apr 23, 2025Raised $16.5 million in a private offering of equity²⁴ Form D: 3 investors so far Form D
4. Nov 1, 2023Filed a private offering of equity¹³ Form D: $37.5 million offered in all Form D
5. Dec 22, 2022Raised $79.7 million in a private offering of equity¹⁴ Form D: 6 investors so far Form D
6. Apr 28, 2022Raised $62.5 million in a private offering of equity¹⁵ Form D: 14 investors so far Form D

SEC filer profile

How Apnimed, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARApnimed, Inc.¹
• CIK0001745648
• Employer ID (EIN)82-1910611¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address39 John F. Kennedy Street, 4Th Flr., Cambridge, MA 02138¹
• Phone617-500-8880¹
• Shares outstanding41,630,779 as of Sep 4, 2026²⁵
• On EDGAR sinceJul 6, 2018¹
• Filings54 in all: 3 (11), 4 (10), D (9), D/A (6), DRS/A (3), 8-K (2), S-8 (2), SCHEDULE 13G (2)¹
  All 17 form types

  10-Q (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1)

• Latest filingsQuarterly report (10-Q) Sep 8, 2026
  Latest 8-K (8-K) Sep 8, 2026